- Home
- MGRX vs PRPO Comparison
MGRX vs PRPO Comparison
Compare MGRX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- PRPO
- Stock Information
- Founded
- MGRX 2021
- PRPO N/A
- Country
- MGRX United States
- PRPO United States
- Employees
- MGRX N/A
- PRPO N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- MGRX Technology
- PRPO Industrials
- Exchange
- MGRX Nasdaq
- PRPO Nasdaq
- Market Cap
- MGRX 23.3M
- PRPO 22.0M
- IPO Year
- MGRX 2023
- PRPO N/A
- Fundamental
- Price
- MGRX $2.27
- PRPO $19.51
- Analyst Decision
- MGRX
- PRPO
- Analyst Count
- MGRX 0
- PRPO 0
- Target Price
- MGRX N/A
- PRPO N/A
- AVG Volume (30 Days)
- MGRX 201.9K
- PRPO 18.4K
- Earning Date
- MGRX 11-13-2025
- PRPO 11-05-2025
- Dividend Yield
- MGRX N/A
- PRPO N/A
- EPS Growth
- MGRX N/A
- PRPO N/A
- EPS
- MGRX N/A
- PRPO N/A
- Revenue
- MGRX $516,030.00
- PRPO $21,242,000.00
- Revenue This Year
- MGRX N/A
- PRPO N/A
- Revenue Next Year
- MGRX N/A
- PRPO N/A
- P/E Ratio
- MGRX N/A
- PRPO N/A
- Revenue Growth
- MGRX N/A
- PRPO 27.05
- 52 Week Low
- MGRX $1.32
- PRPO $3.90
- 52 Week High
- MGRX $7.66
- PRPO $22.38
- Technical
- Relative Strength Index (RSI)
- MGRX 61.49
- PRPO 69.65
- Support Level
- MGRX $2.07
- PRPO $19.40
- Resistance Level
- MGRX $2.48
- PRPO $22.38
- Average True Range (ATR)
- MGRX 0.28
- PRPO 1.31
- MACD
- MGRX 0.01
- PRPO 0.48
- Stochastic Oscillator
- MGRX 67.51
- PRPO 65.56
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.